Updates are available Correction dated 2022-11-03
Click to view Correction: https://doi.org/10.1186/s13075-022-02940-5
-
Authors
Bergman, Martin
Tundia, Namita
Martin, Naomi
Suboticki, Jessica L.
Patel, Jayeshkumar
Goldschmidt, Debbie
Song, Yan
Wright, Grace C.
-
Funding
Funding for this research was provided by:
abbvie, inc.
- License Information
-
More Information
Article History
Received: 19 July 2021
Accepted: 13 May 2022
First Online: 24 June 2022
Change Date: 3 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13075-022-02940-5
Declarations
:
: The protocol was approved by an independent ethics committees or institutional review board at all study sites. All participants provided written informed consent prior to enrollment. The registered clinical trial was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and is consistent with the International Conference on Harmonization Good Clinical Practice and Good Epidemiology Practices, and all applicable local regulatory requirements. All patient data were de-identified and complied with patient confidentiality requirements.
: Not applicable.
: MB is a consultant/speaker for AbbVie, Amgen, BMS, Genentech/Roche, Gilead, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi/Regeneron; and shareholder of Johnson & Johnson (parent company of Janssen).GCW has received speaker and consulting fees from AbbVie and BMS.NM, JLS, and JP are employees and stockholders of AbbVie.NT is a former employee of AbbVie and may hold stock.DG and YS are employees of Analysis Group, Inc., which received consulting fees from AbbVie for this study.
